# ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

> **NCT00081042** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation

## Key facts

- **NCT ID:** NCT00081042
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2010-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081042, "ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00081042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*